Literature DB >> 22885612

Pulmonary rehabilitation in patients with bronchiectasis: pulmonary function, arterial blood gases, and the 6-minute walk test.

Mafalda van Zeller1, Patrícia Caetano Mota, Adelina Amorim, Paulo Viana, Paula Martins, Luís Gaspar, Venceslau Hespanhol, Isabel Gomes.   

Abstract

BACKGROUND: Information regarding the effects of pulmonary rehabilitation (PR) on pulmonary function (PF), arterial blood gases (ABG), and 6-minute walk distance (6MWD) in patients with bronchiectasis is scant in the literature.
METHODS: To evaluate the effects of PR on these indices in this population, a retrospective evaluation of those who attended PR from 2007 to 2010, was made. Pulmonary rehabilitation lasted a mean of 12 weeks and included cycle ergometer exercise for 30 minutes, 3 times per week, with additional upper limbs and quadriceps training. PF, ABG, and 6MWD were evaluated before and after PR to determine the potential influence of gender, exacerbations, underlying cause of bronchiectasis, severity of obstruction, and colonization with bacteria.
RESULTS: Forty-one patients (48.8% males; median age, 54 years) were included; 25 had severe obstruction and 19 were colonized with bacteria. Following PR, no significant changes were detected in PF or ABG. Median 6MWD before PR was 425 m and post-PR was 450 m (P = .431). Outcomes did not show any interaction with gender, colonization, or exacerbations. However, patients with idiopathic bronchiectasis did show a significant improvement in forced vital capacity in percent of predicted and residual volume after PR (P = .016 and .048, respectively). Patients with severe obstruction showed a statistically significant decrease in percent of predicted residual volume (P = .025).
CONCLUSION: There appears to be a beneficial impact of PR on PF in certain groups of patients with bronchiectasis. In addition, PR indications and protocols for patients with bronchiectasis may need to be adapted to accommodate specific patients, so that expressive exercise capacity improvement can be achieved.

Entities:  

Mesh:

Year:  2012        PMID: 22885612     DOI: 10.1097/HCR.0b013e3182631314

Source DB:  PubMed          Journal:  J Cardiopulm Rehabil Prev        ISSN: 1932-7501            Impact factor:   2.081


  5 in total

1.  Assessing quadriceps muscle strength as a tool to determine the approach to and prognosis in COPD patients.

Authors:  Luciana Dias Chiavegato
Journal:  J Bras Pneumol       Date:  2015 Jul-Aug       Impact factor: 2.624

2.  Sedentary behaviour and physical activity in bronchiectasis: a cross-sectional study.

Authors:  Judy M Bradley; Jason J Wilson; Kate Hayes; Lisa Kent; Suzanne McDonough; Mark A Tully; Ian Bradbury; Alison Kirk; Denise Cosgrove; Rory Convery; Martin Kelly; Joseph Stuart Elborn; Brenda O'Neill
Journal:  BMC Pulm Med       Date:  2015-05-13       Impact factor: 3.317

3.  Effects of exercise on secretion transport, inflammation, and quality of life in patients with noncystic fibrosis bronchiectasis: Protocol for a randomized controlled trial.

Authors:  Daniele Oliveira Dos Santos; Hugo Celso Dutra de Souza; José Antônio Baddini-Martinez; Ercy Mara Cipulo Ramos; Ada Clarice Gastaldi
Journal:  Medicine (Baltimore)       Date:  2018-02       Impact factor: 1.817

4.  The short and long term effects of exercise training in non-cystic fibrosis bronchiectasis--a randomised controlled trial.

Authors:  Annemarie L Lee; Catherine J Hill; Nola Cecins; Sue Jenkins; Christine F McDonald; Angela T Burge; Linda Rautela; Robert G Stirling; Philip J Thompson; Anne E Holland
Journal:  Respir Res       Date:  2014-04-15

5.  Does home-based pulmonary rehabilitation improve functional capacity, peripheral muscle strength and quality of life in patients with bronchiectasis compared to standard care?

Authors:  Anderson José; Anne E Holland; Cristiane S de Oliveira; Jessyca P R Selman; Rejane A S de Castro; Rodrigo A Athanazio; Samia Z Rached; Alberto Cukier; Rafael Stelmach; Simone Dal Corso
Journal:  Braz J Phys Ther       Date:  2017-08-19       Impact factor: 3.377

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.